OncoGenex Pharmaceuticals Company Profile (NASDAQ:OGXI)

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals logoOncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company's segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company's product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OGXI
  • CUSIP: 68230A10
Key Metrics:
  • Previous Close: $0.63
  • 50 Day Moving Average: $0.58
  • 200 Day Moving Average: $0.52
  • 52-Week Range: $0.33 - $1.42
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.11
  • P/E Growth: 0.00
  • Market Cap: $18.91M
  • Outstanding Shares: 30,020,000
  • Beta: 1.79
Profitability:
  • Net Margins: -94.64%
  • Return on Equity: -50.34%
  • Return on Assets: -33.95%
Debt:
  • Current Ratio: 3.24%
  • Quick Ratio: 3.24%
Additional Links:
Companies Related to OncoGenex Pharmaceuticals:

Analyst Ratings

Consensus Ratings for OncoGenex Pharmaceuticals (NASDAQ:OGXI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Show:
DateFirmActionRatingPrice TargetDetails
1/22/2016Needham & Company LLCLower Price TargetBuy$6.00 -> $3.00View Rating Details
1/21/2016Royal Bank Of CanadaLower Price TargetSector Perform$1.60 -> $1.00View Rating Details
12/2/2015Stifel NicolausDowngradeBuy -> HoldView Rating Details
9/24/2015William BlairReiterated RatingBuy$6.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2017        
2/23/2017Q4 2016($0.28)N/AView Earnings Details
11/10/2016Q316($0.26)($0.12)ViewN/AView Earnings Details
8/4/2016Q216($0.22)($0.23)$1.17 million$2.10 millionViewN/AView Earnings Details
5/12/2016Q116($0.12)($0.12)$4.09 million$2.90 millionViewListenView Earnings Details
3/9/2016Q4($0.15)($0.06)ViewN/AView Earnings Details
11/12/2015Q3($0.17)($0.16)ViewListenView Earnings Details
8/13/2015Q2$0.34($0.26)ViewListenView Earnings Details
5/14/2015Q115($0.34)($0.20)$4.66 million$1.40 millionViewListenView Earnings Details
3/26/2015Q414($0.30)($0.27)$4.30 million$5.70 millionViewN/AView Earnings Details
10/30/2014($0.38)($0.23)ViewN/AView Earnings Details
8/7/2014($0.55)($0.47)ViewN/AView Earnings Details
4/30/2014($0.50)($0.59)ViewN/AView Earnings Details
3/11/2014Q113($0.66)($0.45)$10.20 million$8.60 millionViewN/AView Earnings Details
11/8/2012Q312($0.49)($0.40)$4.52 million$6.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Current Year EPS Consensus Estimate: $-0.78 EPS
Next Year EPS Consensus Estimate: $-0.57 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.07)($0.07)($0.07)
Q2 20161($0.27)($0.27)($0.27)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
Insider Ownership Percentage: 3.30%
Institutional Ownership Percentage: 18.54%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/19/2016John BencichCFOSell1,380$0.57$786.60View SEC Filing  
6/13/2016Cindy JacobsCMOSell1,437$1.03$1,480.11View SEC Filing  
6/13/2016Scott Daniel CormackCEOSell4,856$1.03$5,001.68View SEC Filing  
3/15/2016Cindy JacobsCMOSell3,254$0.83$2,700.82View SEC Filing  
3/15/2016John BencichCFOSell834$0.83$692.22View SEC Filing  
3/15/2016Scott Daniel CormackCEOSell12,033$0.83$9,987.39View SEC Filing  
8/18/2015John BencichCFOSell1,427$2.76$3,938.52View SEC Filing  
6/12/2015Cindy JacobsCMOSell1,408$2.69$3,787.52View SEC Filing  
6/12/2015Scott Daniel CormackCEOSell4,571$2.69$12,295.99View SEC Filing  
5/20/2015Cindy JacobsCMOSell2,092$1.88$3,932.96View SEC Filing  
5/20/2015Scott Daniel CormackCEOSell7,543$1.88$14,180.84View SEC Filing  
8/13/2014Cindy JacobsCMOSell5,650$3.17$17,910.50View SEC Filing  
8/13/2014Scott Daniel CormackCEOSell18,341$3.17$58,140.97View SEC Filing  
3/17/2014Cindy JacobsCMOSell1,250$12.25$15,312.50View SEC Filing  
3/17/2014Scott Daniel CormackCEOSell4,634$12.25$56,766.50View SEC Filing  
8/19/2013Cindy JacobsCMOSell1,364$8.68$11,839.52View SEC Filing  
8/19/2013Scott Daniel CormackCEOSell3,112$8.68$27,012.16View SEC Filing  
3/12/2013Scott Daniel CormackCEOSell2,134$11.90$25,394.60View SEC Filing  
8/15/2012Jack GoldsteinDirectorBuy1,000$14.38$14,380.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for OncoGenex Pharmaceuticals (NASDAQ:OGXI)
DateHeadline
us.rd.yahoo.com logoOncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the American Society of Clinical Oncology (ASCO) 2017 Genitourinary Cancers Symposium (NASDAQ:OGXI)
us.rd.yahoo.com - February 22 at 7:05 PM
us.rd.yahoo.com logo9:01 am OncoGenex Pharma announces that apatorsen results from two randomized Phase 2 clinical trials were presented at the American Society of Clinical Oncology 2017 Genitourinary Cancers Symposium; Clinical data from trials in bladder and (NASDAQ:OGXI)
us.rd.yahoo.com - February 22 at 7:05 PM
News IconAnalysts Peer Into Their Crystal Balls For OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI): Where Is It headed? - Winfield Review (NASDAQ:OGXI)
winfieldreview.com - February 21 at 5:51 PM
finance.yahoo.com logoOncoGenex Pharmaceuticals, Inc. Announces Phase 2 Apatorsen Data for Two Clinical Trials Presented at the ... - Yahoo Finance (NASDAQ:OGXI)
finance.yahoo.com - February 21 at 5:51 PM
News IconRange Watch on Technical Indicators for OncoGenex Pharmaceuticals Inc. (OGXI) - Baxter Review (NASDAQ:OGXI)
baxternewsreview.com - February 16 at 11:34 PM
finance.yahoo.com logoOncoGenex to Report Year End 2016 Financial Results on Feb. 23, 2017 (NASDAQ:OGXI)
finance.yahoo.com - February 16 at 6:34 PM
News IconStock Watch for OncoGenex Pharmaceuticals Inc. (OGXI) - Davidson Register (NASDAQ:OGXI)
davidsonregister.com - February 10 at 7:58 PM
News IconTrading Radar: Zooming in on Shares of OncoGenex Pharmaceuticals Inc. (OGXI) - Piedmont Register (NASDAQ:OGXI)
piedmontregister.com - February 9 at 5:57 AM
News IconCalibrating the Trade: Watching Technicals on Shares of OncoGenex Pharmaceuticals Inc. (OGXI) - Rives Journal (NASDAQ:OGXI)
rivesjournal.com - February 9 at 5:57 AM
News IconInvestor Sphere: Keeping an Eye on Levels for OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - February 3 at 6:01 AM
News IconAverage Directional Index in Review for OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - February 2 at 1:08 AM
News IconBrexit: MPs to start debate on bill triggering European Union departure (NASDAQ:OGXI)
ekosvoice.com - February 1 at 1:00 AM
News IconThe Wells Fargo & Company (WFC) Position Increased by Delta Lloyd NV (NASDAQ:OGXI)
cote-ivoire.com - January 31 at 2:37 AM
News IconNarrowing in on Trading Indicators for OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - January 30 at 7:41 PM
News IconKeen Investors Taking a Look at OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Prospect Journal (NASDAQ:OGXI)
prospectjournal.com - January 30 at 7:41 PM
News IconNewsworthy Wonder Stock: Penny Stock Investors Looking at OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Nelson Research (NASDAQ:OGXI)
nelsonobserver.com - January 29 at 12:09 AM
News IconOncoGenex Pharmaceuticals Inc. (OGXI) - Latest Broker Consensus ... - NewsDen (NASDAQ:OGXI)
newsden.net - January 28 at 7:07 PM
News IconOncoGenex Pharmaceuticals Inc. (OGXI) Broker Price Targets For The Coming Week (NASDAQ:OGXI)
itapunta.com - January 27 at 5:01 AM
News IconWhat Are the Technicals Saying About These Shares: OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - January 27 at 12:01 AM
News IconEarnings in Full Force, Analysts Take Aim at OncoGenex Pharmaceuticals Inc. (NASDAQ:OGXI) - Wall Street Beacon (NASDAQ:OGXI)
wsbeacon.com - January 27 at 12:01 AM
News IconCCI Focus on Shares of OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - January 24 at 7:47 PM
News IconInvesting Focus: Indicators in View on Shares of OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - January 24 at 12:22 AM
News IconOncoGenex Pharmaceuticals Inc. (OGXI) Valuation According To ... - UK Market News (NASDAQ:OGXI)
www.ukmarketnews.co.uk - January 22 at 11:49 PM
News IconTrading Corner: Eye on Technical Levels for OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - January 21 at 6:58 AM
News IconA Keen Look at These Shares: OncoGenex Pharmaceuticals, Inc ... - Prospect Journal (NASDAQ:OGXI)
prospectjournal.com - January 21 at 6:58 AM
News IconEquity Insight: Indicator Review for OncoGenex Pharmaceuticals Inc. (OGXI) - Sherwood Daily (NASDAQ:OGXI)
sherwooddaily.com - January 17 at 7:23 PM
News IconIs There Any Upside to This Stock Under $5: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Prospect Journal (NASDAQ:OGXI)
prospectjournal.com - January 17 at 7:23 PM
News IconA Look at this Riveting Stock: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Prospect Journal (NASDAQ:OGXI)
prospectjournal.com - January 17 at 7:23 PM
bizjournals.com logoAfter reverse takeover, Bothell's OncoGenex changes name, focuses on smoking cessation drug (NASDAQ:OGXI)
www.bizjournals.com - January 17 at 7:23 PM
News IconIs This Equity Ready for a Breakout: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Prospect Journal (NASDAQ:OGXI)
prospectjournal.com - January 12 at 7:37 PM
News IconCan This Stock Pick Up Any Momentum: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Prospect Journal (NASDAQ:OGXI)
prospectjournal.com - January 12 at 12:40 AM
News IconOncoGenex Pharmaceuticals to Acquire Achieve Life Science Inc. in All-Stock Transaction (NASDAQ:OGXI)
www.bctechnology.com - January 11 at 7:39 PM
News IconOncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) shows weekly volitility of 17.49% - The Newburgh Press (NASDAQ:OGXI)
newburghpress.com - January 10 at 7:52 PM
News IconOncoGenex Pharmaceuticals Inc (NASDAQ:OGXI) To Merge Into Achieve Life Science Inc - Journal Transcript (NASDAQ:OGXI)
www.journaltranscript.com - January 9 at 4:44 AM
News IconChecking on Levels for OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Wall Street Beacon (NASDAQ:OGXI)
wsbeacon.com - January 8 at 4:20 AM
streetinsider.com logoOncoGenex Pharma (OGXI) to Merge with Achieve Life Science - StreetInsider.com (NASDAQ:OGXI)
www.streetinsider.com - January 6 at 7:44 PM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:OGXI)
biz.yahoo.com - January 6 at 7:44 PM
streetinsider.com logoOncoGenex Pharma (OGXI) to Merge with Achieve Life Science (NASDAQ:OGXI)
www.streetinsider.com - January 5 at 11:11 PM
marketexclusive.com logoONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:OGXI)
marketexclusive.com - January 5 at 11:11 PM
finance.yahoo.com logo4:32 pm OncoGenex Pharma will acquire privately held Achieve Life Science in an all-stock transaction; co will be renamed 'Achieve Life Sciences' following completion of merger --shares halted-- (NASDAQ:OGXI)
finance.yahoo.com - January 5 at 11:11 PM
biz.yahoo.com logoONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors o (NASDAQ:OGXI)
biz.yahoo.com - January 5 at 11:11 PM
publicnow.com logoOncoGenex Pharmaceuticals, Inc. and Achieve Life Science, Inc. Announce Definitive Merger Agreement (NASDAQ:OGXI)
www.publicnow.com - January 5 at 11:11 PM
News IconReviewing the Levels for OncoGenex Pharmaceuticals, Inc ... - Wall Street Beacon (NASDAQ:OGXI)
wsbeacon.com - January 2 at 6:51 PM
News IconOncoGenex Pharmaceuticals Inc. (OGXI) Analyst Coverage - NewsDen (NASDAQ:OGXI)
newsden.net - December 31 at 6:44 PM
News IconWatching the Numbers for OncoGenex Pharmaceuticals, Inc ... - Business Daily Leader (NASDAQ:OGXI)
businessdailyleader.com - December 22 at 12:52 AM
News IconStock Survey: Checking Levels for OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Business Daily Leader (NASDAQ:OGXI)
businessdailyleader.com - December 20 at 1:14 PM
News IconLevels in View for OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Wall Street Beacon (NASDAQ:OGXI)
wsbeacon.com - December 20 at 1:14 PM
News IconMarket Focus: Zooming in on Shares of OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Wall Street Beacon (NASDAQ:OGXI)
wsbeacon.com - December 17 at 12:46 AM
News IconOncoGenex Pharmaceuticals Inc. (OGXI) Valuation According To Analysts - UK Market News (NASDAQ:OGXI)
www.ukmarketnews.co.uk - December 15 at 5:45 AM
News IconCompany Shares in Review: OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) - Business Daily Leader (NASDAQ:OGXI)
businessdailyleader.com - December 14 at 5:29 AM

Social

What is OncoGenex Pharmaceuticals' stock symbol?

OncoGenex Pharmaceuticals trades on the NASDAQ under the ticker symbol "OGXI."

When will OncoGenex Pharmaceuticals announce their earnings?

OncoGenex Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 7th 2017.

Who owns OncoGenex Pharmaceuticals stock?

OncoGenex Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (3.45%). Company insiders that own OncoGenex Pharmaceuticals stock include Cindy Jacobs, John Bencich and Scott Daniel Cormack.

Who bought OncoGenex Pharmaceuticals stock? Who is buying OncoGenex Pharmaceuticals stock?

OncoGenex Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy OncoGenex Pharmaceuticals stock?

Shares of OncoGenex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of OncoGenex Pharmaceuticals stock cost?

One share of OncoGenex Pharmaceuticals stock can currently be purchased for approximately $0.63.

OncoGenex Pharmaceuticals (NASDAQ:OGXI) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)

Earnings History Chart

Earnings by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)

Dividend History Chart

Dividend Payments by Quarter for OncoGenex Pharmaceuticals (NASDAQ:OGXI)

Last Updated on 2/23/2017 by MarketBeat.com Staff